Ascites Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | BioVie, Ocelot Bio, Sanofi, Neovii Biotech, Grifols Therapeutics, Movetis

June 01
10:16 2023
Ascites Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | BioVie, Ocelot Bio, Sanofi, Neovii Biotech, Grifols Therapeutics, Movetis
DelveInsight’s “Ascites Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ascites.

DelveInsight’s “Ascites Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Ascites market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ascites Market Forecast

 

Some of the key facts of the Ascites Market Report: 

  • The Ascites market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • DelveInsight estimates that there were 242,201 occurrences of ascites caused by cirrhosis in the 7MM population in 2021. These cases are anticipated to rise at a respectable CAGR from 2019 to 2032, according to estimations from DelveInsight
  • There were over 150,291 occurrences of ascites caused by cirrhosis in the US in 2021. According to the malignancy, there were 8,683, 3,621, 12,820, and 10,454 instances of ascites from ovarian, stomach, breast, and colorectal cancer in the US in 2021, respectively
  • Ascites caused by cirrhosis is estimated to have occurred in 20,104 instances in Germany in 2021. Ascites cases related to ovarian, stomach, breast, and colorectal cancer were reported to be 5,009, 1,914, 3,495, and 3,888 in Germany in 2021, respectively
  • Key Ascites Companies: BioVie, Ocelot Bio, Sanofi, Neovii Biotech, Grifols Therapeutics, Movetis, BioVie Inc., Otsuka Beijing Research Institute, Jiangsu Simcere Pharma, Ocelot Bio, Inc., and others
  • Key Ascites Therapies: BIV201 (Terlipressin), OCE-205, aflibercept, catumaxomab, Albutein, M0002, satavaptan (SR121463B), BIV201, Tolvaptan, Endostar, OCE-205, and others
  • The Ascites epidemiology based on type-specific cases analyzed that there were 26,841 and 122,277 cases of Grade I and Grade II and III ascites due to cirrhosis in the United States
  • The Ascites market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ascites pipeline products will significantly revolutionize the Ascites market dynamics.

 

Ascites Overview

A surplus of intraperitoneal fluid is referred to as ascites (hydroperitoneum is a rare synonym). Ascites is a disorder where fluid builds up in the abdominal cavities. If ascites is bad, it could hurt.

 

Get a Free sample for the Ascites Market Report 

https://www.delveinsight.com/report-store/ascites-market

 

Ascites Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Ascites Epidemiology Segmentation:

The Ascites market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Ascites
  • Prevalent Cases of Ascites by severity
  • Gender-specific Prevalence of Ascites
  • Diagnosed Cases of Episodic and Chronic Ascites

 

Download the report to understand which factors are driving Ascites epidemiology trends @ Ascites Epidemiology Forecast

 

Ascites Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ascites market or expected to get launched during the study period. The analysis covers Ascites market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ascites Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Ascites Therapies and Key Companies

  • BIV201 (Terlipressin): BioVie
  • OCE-205: Ocelot Bio
  • aflibercept: Sanofi
  • catumaxomab: Neovii Biotech
  • Albutein: Grifols Therapeutics
  • M0002: Movetis
  • satavaptan (SR121463B): Sanofi
  • BIV201: BioVie Inc.
  • Tolvaptan: Otsuka Beijing Research Institute
  • Satavaptan: Sanofi
  • Endostar: Jiangsu Simcere Pharma
  • OCE-205: Ocelot Bio, Inc

 

Discover more about therapies set to grab major Ascites market share @ Ascites Treatment Market

 

Ascites Market Strengths

  • The rise in the patient population of underlying conditions of ascites such as liver cirrhosis, alcoholism, kidney or heart failure, malignancy, etc. might contribute to an increase inthe patient population of ascites

 

Ascites Market Opportunities

  • Limited approved, and emerging therapies in the pipeline offer a great opportunity for the investment and development of novel therapies

 

Scope of the Ascites Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Ascites Companies: BioVie, Ocelot Bio, Sanofi, Neovii Biotech, Grifols Therapeutics, Movetis, BioVie Inc., Otsuka Beijing Research Institute, Jiangsu Simcere Pharma, Ocelot Bio, Inc., and others
  • Key Ascites Therapies: BIV201 (Terlipressin), OCE-205, aflibercept, catumaxomab, Albutein, M0002, satavaptan (SR121463B), BIV201, Tolvaptan, Endostar, OCE-205, and others
  • Ascites Therapeutic Assessment: Ascites current marketed and Ascites emerging therapies
  • Ascites Market Dynamics: Ascites market drivers and Ascites market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Ascites Unmet Needs, KOL’s views, Analyst’s views, Ascites Market Access and Reimbursement 

 

To know more about Ascites companies working in the treatment market, visit @ Ascites Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Ascites Market Report Introduction

2. Executive Summary for Ascites

3. SWOT analysis of Ascites

4. Ascites Patient Share (%) Overview at a Glance

5. Ascites Market Overview at a Glance

6. Ascites Disease Background and Overview

7. Ascites Epidemiology and Patient Population

8. Country-Specific Patient Population of Ascites 

9. Ascites Current Treatment and Medical Practices

10. Ascites Unmet Needs

11. Ascites Emerging Therapies

12. Ascites Market Outlook

13. Country-Wise Ascites Market Analysis (2019–2032)

14. Ascites Market Access and Reimbursement of Therapies

15. Ascites Market Drivers

16. Ascites Market Barriers

17.  Ascites Appendix

18. Ascites Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories